Overview:
The Inflation Reduction Act and the resulting Medicare Part D price negotiations are shaping up to be the most far reaching of any event impacting pharma manufacturing in recent history.
Although the first set of negotiated prices for selected drugs will not take effect until January 1, 2026, the immediate impact has been fast and furious - more than a dozen lawsuits have been filed by pharmaceutical companies, advocacy groups and the US Chamber of Commerce. Industry media is ablaze with discussions on how price negotiations will impact the pricing of non-selected same-class drugs and biosimilars, as well as future drug development in general.
Key discussion topics:
With the first-round negotiated prices for selected drugs to be made public on September 1, 2024, companies are preparing themselves for the second round of selections. This timely webinar will provide an update on:
- To-date information on the legal actions, existing price negotiations, and market reactions
- Drugs likely to be selected for the second round and their same-class competitors who will be impacted
- The changes and impact of out-of-pocket costs on enrollees
- Price negotiation benchmarking on selected drugs compared to net pricing on competitors
- How manufacturers should prepare for the overall impact to the industry
- Part D plan utilization management
Register for this webinar today to understand the profound impact of the Inflation Reduction Act and Medicare Part D price negotiations on the pharmaceutical industry.
Who should attend?
This webinar will benefit pharmaceutical and biotech professionals in the following areas:
- Market access/Marketing/Managed markets/Market research
- Real world evidence
- Regulatory affairs
- Channel marketing
- Clinical research
- Competitive intelligence
- Government affairs
- Health economics and outcomes research
What you will learn:
Attendees will learn about:
- The ongoing legal challenges initiated by pharmaceutical companies and other stakeholders against the Inflation Reduction Act’s price negotiation provisions
- Drugs likely to be targeted in the upcoming rounds of Medicare Part D price negotiations
- The impact of changes to enrollees and drug manufacturers around reductions in patient out-of-pocket costs
- The future impact on Part D plan utilization management
Presenters:
Mark McCoy, RPh, MBA
Mark McCoy, RPh, MBA is Director, Client Engagement Pricing Market Access and Reimbursement since 2022. His managed market and brand strategy experience includes work at Invenivhealth, Palio+Ignite, Syneos, GSK and Schering Plough. He earned his BS and MBA from Northeastern University.
Amith Shetty, Pharm.D, RPh
Amith Shetty, Pharm.D, RPh has been a Senior Clinical & Market Access Specialist with 91黑料 since 2022. He holds over 10 years of experience in healthcare, including roles as a community pharmacist, and a clinical preceptor at Thomas Jefferson University. He earned his Doctor of Pharmacy degree from Thomas Jefferson University.
Dr. Xin Zhao
Dr. Xin Zhao is Principal, Global Market Access for 91黑料. She holds more than 15 years of experience in life sciences focused on drug commercialisation, market access and pricing strategies. She previously worked at GSK, Norstrella, and Citeline. She earned her doctorate from Cardiff University/Prifysgol Caerdydd.